Arrowhead Pharmaceuticals

This study tested giving nine additional doses of an experimental drug called ARC-520 to people with chronic hepatitis B who had previously responded well to it. All 12 participants continued taking their standard daily hepatitis B medication alongside the ARC-520 injections. The…

This early-stage study tested an inhaled drug called ARO-MUC5AC, designed to reduce harmful mucus in the lungs. It aimed to see if the drug was safe and how it worked in healthy volunteers and people with moderate-to-severe asthma or COPD. The study was terminated, meaning it was…

This study tested whether adding an experimental drug called ARC-520 to standard hepatitis B medications could better reduce signs of the virus in the blood. It involved 58 adults with a specific type of chronic hepatitis B who were already taking standard antiviral pills. The tr…

This early-stage study tested a new drug called ARC-AAT to see if it was safe and could lower harmful protein levels in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. The trial involved 65 healthy volunteers and patients with …

This early-stage study aimed to test the safety and effects of an experimental drug called ARO-ENaC. It involved healthy volunteers and people with cystic fibrosis to see how their bodies handled the drug and if it helped lung function. The study was terminated early, and its mai…

This study tested whether adding a new intravenous drug called ARC-520 to standard oral medications (entecavir or tenofovir) could more effectively reduce the amount of Hepatitis B virus in the body. It involved a small group of adults with a specific type of chronic Hepatitis B …

This study tested an experimental drug called ARC-520, given alone or with other standard hepatitis B medications, in people with chronic hepatitis B infection. The main goal was to see if the treatment could safely and significantly reduce the amount of hepatitis B virus in the …

This study tested whether adding an experimental drug called ARC-520 to standard hepatitis B medications could better reduce the amount of virus in the body. About 32 adults with a specific type of chronic hepatitis B received either ARC-520 or a placebo injection alongside their…

This study tested whether adding a new investigational drug called ARC-520 to the standard Hepatitis B medication entecavir could better control the virus. It involved 58 adults with chronic Hepatitis B and aimed to see if the combination could safely and significantly reduce lev…

This was an early-stage study to test the safety and effects of a new drug called ARC-521 for people with chronic Hepatitis B. It involved 47 healthy volunteers and patients to see how their bodies handled different doses and if the drug could reduce the virus. The main goal was …